Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma

In conclusion, targeted therapy with BRAF/MEK inhibitors holds great promise for improving outcomes and quality of life for patients with BRAF-mutated craniopharyngiomas. However, additional research is needed to address the questions that remain about its optimal use and integration into comprehensive treatment plans.
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research